首页 > 最新文献

Nuklearmedizin-nuclear Medicine最新文献

英文 中文
Radioiodine Uptake of a Benign Peritoneal Cyst on 131-I Whole-body Scan in a Patient Treated for Papillary Thyroid Cancer. 131-I全身扫描对良性腹膜囊肿放射性碘摄取的影响。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-04-01 Epub Date: 2021-12-16 DOI: 10.1055/a-1699-1595
Mardjan Dabir, Juliane Limberg, Andreas Krieg, Christina Antke, Lino M Sawicki
{"title":"Radioiodine Uptake of a Benign Peritoneal Cyst on 131-I Whole-body Scan in a Patient Treated for Papillary Thyroid Cancer.","authors":"Mardjan Dabir, Juliane Limberg, Andreas Krieg, Christina Antke, Lino M Sawicki","doi":"10.1055/a-1699-1595","DOIUrl":"https://doi.org/10.1055/a-1699-1595","url":null,"abstract":"","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 2","pages":"130-131"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39846662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml. 18F-PSMA-1007 PET/CT在PSA <10 ng/ml明确治疗后早期复发前列腺癌患者中的诊断价值
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-04-01 DOI: 10.1055/a-1759-1603
T. Lengana, I. Lawal, C. Janse Van Rensburg, K. Mokoala, E. Moshokoa, Sfiso Mazibuko, C. Van de Wiele, A. Maes, M. Vorster, M. Sathekge
AIMThe prostate bed is one of the common sites of early recurrence of prostate cancer. The currently used PSMA ligands (68Ga-PSMA-11 and 99mTc-PSMA) undergo early urinary clearance resulting in interfering physiological activity within and surrounding the prostate. This can result in sites of cancer recurrence being obscured. 18F-PSMA-1007 has an advantage of delayed urinary clearance thus the prostate region is reviewed without any interfering physiological activity. The aim of this study was to determine the diagnostic performance of 18F-PSMA-1007 PET/CT in patients with early biochemical recurrence after definitive therapy.METHODSForty-six Prostate cancer (mean age 66.7±7.5, range 48-87 years) presenting with biochemical recurrence (median PSA 1.6ng/ml, range 0.1-10.0) underwent non-contrast-enhanced 18F-PSMA-1007 PET/CT. PET/CT findings were evaluated qualitatively and semiquantitatively (SUVmax) and compared to the results of histology, Gleason grade, and conventional imaging.RESULTSTwenty-four of the 46 (52.2%) patients demonstrated a site of recurrence on 18F-PSMA-1007 PET/CT. Oligometastatic disease was detected in 15 (32.6%) of these patients. Of these 10 (37.5%) demonstrated intra-prostatic recurrence, lymph node disease was noted in 11 (45.8%) whilst two patients demonstrated skeletal metastases. The detection rates for PSA levels 0-<0.5, 0.5-<1, 1-2, >2 were 31.3%, 33.3%, 55.6% and 72.2% respectively. 7 (29.2%) of the positive patients had been described as negative or equivocal on conventional imaging. An optimal PSA cut-off level of 1.3ng/ml was found.CONCLUSION18F-PSMA-1007 demonstrated good diagnostic performance detecting sites of recurrence. Its ability to detect sites of recurrence in the setting of early biochemical recurrence will have a significant impact on patient management.
目的前列腺床是前列腺癌早期复发的常见部位之一。目前使用的PSMA配体(68Ga-PSMA-11和99mTc-PSMA)在早期尿清除率导致前列腺内部和周围的生理活动受到干扰。这可能导致癌症复发的部位模糊不清。18F-PSMA-1007具有延迟尿液清除的优点,因此在没有任何干扰生理活动的情况下对前列腺区域进行检查。本研究的目的是确定18F-PSMA-1007 PET/CT在明确治疗后早期生化复发患者中的诊断价值。方法46例前列腺癌患者(平均年龄66.7±7.5岁,年龄范围48 ~ 87岁)进行了18F-PSMA-1007 PET/CT非增强检查(PSA中位数为1.6ng/ml,范围0.1 ~ 10.0)。PET/CT结果进行定性和半定量评估(SUVmax),并与组织学、Gleason分级和常规影像学结果进行比较。结果46例患者中24例(52.2%)在18F-PSMA-1007 PET/CT上显示有复发部位。这些患者中有15例(32.6%)检测到少转移性疾病。其中10例(37.5%)出现前列腺内复发,11例(45.8%)出现淋巴结疾病,2例出现骨骼转移。0 ~ 2级PSA检出率分别为31.3%、33.3%、55.6%、72.2%。7例(29.2%)阳性患者在常规影像学上表现为阴性或模棱两可。最佳PSA临界值为1.3ng/ml。结论18f - psma -1007对复发部位有较好的诊断效果。它在早期生化复发的情况下检测复发部位的能力将对患者管理产生重大影响。
{"title":"The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.","authors":"T. Lengana, I. Lawal, C. Janse Van Rensburg, K. Mokoala, E. Moshokoa, Sfiso Mazibuko, C. Van de Wiele, A. Maes, M. Vorster, M. Sathekge","doi":"10.1055/a-1759-1603","DOIUrl":"https://doi.org/10.1055/a-1759-1603","url":null,"abstract":"AIM\u0000The prostate bed is one of the common sites of early recurrence of prostate cancer. The currently used PSMA ligands (68Ga-PSMA-11 and 99mTc-PSMA) undergo early urinary clearance resulting in interfering physiological activity within and surrounding the prostate. This can result in sites of cancer recurrence being obscured. 18F-PSMA-1007 has an advantage of delayed urinary clearance thus the prostate region is reviewed without any interfering physiological activity. The aim of this study was to determine the diagnostic performance of 18F-PSMA-1007 PET/CT in patients with early biochemical recurrence after definitive therapy.\u0000\u0000\u0000METHODS\u0000Forty-six Prostate cancer (mean age 66.7±7.5, range 48-87 years) presenting with biochemical recurrence (median PSA 1.6ng/ml, range 0.1-10.0) underwent non-contrast-enhanced 18F-PSMA-1007 PET/CT. PET/CT findings were evaluated qualitatively and semiquantitatively (SUVmax) and compared to the results of histology, Gleason grade, and conventional imaging.\u0000\u0000\u0000RESULTS\u0000Twenty-four of the 46 (52.2%) patients demonstrated a site of recurrence on 18F-PSMA-1007 PET/CT. Oligometastatic disease was detected in 15 (32.6%) of these patients. Of these 10 (37.5%) demonstrated intra-prostatic recurrence, lymph node disease was noted in 11 (45.8%) whilst two patients demonstrated skeletal metastases. The detection rates for PSA levels 0-<0.5, 0.5-<1, 1-2, >2 were 31.3%, 33.3%, 55.6% and 72.2% respectively. 7 (29.2%) of the positive patients had been described as negative or equivocal on conventional imaging. An optimal PSA cut-off level of 1.3ng/ml was found.\u0000\u0000\u0000CONCLUSION\u000018F-PSMA-1007 demonstrated good diagnostic performance detecting sites of recurrence. Its ability to detect sites of recurrence in the setting of early biochemical recurrence will have a significant impact on patient management.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"20 1","pages":"120-129"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89819026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040 在神经细胞血脉的儿童和青少年身上执行和公布37i mig sgt stigraphin(第3版本),听证内容:2/2020 / awmf参数0040
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-04-01 DOI: 10.1055/a-1778-3052
M. Schmidt, B. Decarolis, C. Franzius, B. Hero, T. Pfluger, J. Rogasch, T. Simon
Die aktualisierte 3. Fassung der 123I-mIBG-Szintigrafie bei Kindern und Jugendlichen berücksichtigt folgende aktuelle Entwicklungen: Die Leitlinie fokussiert auf die diagnostische Anwendung von 123I-mIBG beim Neuroblastom. 131I-mIBG kommt bei der Radionuklidtherapie zum Einsatz. An wenigen Stellen wird auf Besonderheiten des 131I-mIBG bei der Befundung von Posttherapie-Szintigrammen eingegangen. Es werden aktuelle Entwicklungen in der Patientenvorbereitung bei den Medikamenteninterferenzen und Empfehlungen zur Schilddrüsenblockade berücksichtigt. Neue Empfehlungen der zu applizierenden Aktivität werden genannt und die damit assoziierten Probleme diskutiert. Die Bildakquisition unter Berücksichtigung von SPECT bzw. SPECT/CT des Körperstammes inkl. des Kopfes wird berücksichtigt. Die Befundung unter Verwendung des SIOPEN-Scores wird neu aufgenommen. Auf PET bzw. PET/CT mit 18F-DOPA bzw. 68Ga-DotaTATE wird verwiesen.
升级了在儿童与青少年中,循地互动分析包含着各种最新发展:准则将重点放在神经细胞瘤中得典型地神经超一mibg物品的诊断用途上。有少数几处提到了911的特殊特点以目前的进展情况确定提出了一些需要进行的活动的新建议,并讨论了相关问题。拍摄裁判会考虑到身体骨架的SPECT/CT值。头部也被考虑在内。通过公开的拍卖分数的公布被重新进行。PET/ PET(功能68元或68元)被开除。
{"title":"Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040","authors":"M. Schmidt, B. Decarolis, C. Franzius, B. Hero, T. Pfluger, J. Rogasch, T. Simon","doi":"10.1055/a-1778-3052","DOIUrl":"https://doi.org/10.1055/a-1778-3052","url":null,"abstract":"\u0000 Die aktualisierte 3. Fassung der 123I-mIBG-Szintigrafie bei Kindern und Jugendlichen berücksichtigt folgende aktuelle Entwicklungen: Die Leitlinie fokussiert auf die diagnostische Anwendung von 123I-mIBG beim Neuroblastom. 131I-mIBG kommt bei der Radionuklidtherapie zum Einsatz. An wenigen Stellen wird auf Besonderheiten des 131I-mIBG bei der Befundung von Posttherapie-Szintigrammen eingegangen. Es werden aktuelle Entwicklungen in der Patientenvorbereitung bei den Medikamenteninterferenzen und Empfehlungen zur Schilddrüsenblockade berücksichtigt. Neue Empfehlungen der zu applizierenden Aktivität werden genannt und die damit assoziierten Probleme diskutiert. Die Bildakquisition unter Berücksichtigung von SPECT bzw. SPECT/CT des Körperstammes inkl. des Kopfes wird berücksichtigt. Die Befundung unter Verwendung des SIOPEN-Scores wird neu aufgenommen. Auf PET bzw. PET/CT mit 18F-DOPA bzw. 68Ga-DotaTATE wird verwiesen.\u0000","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"35 1","pages":"96-110"},"PeriodicalIF":1.5,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84847691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Radioembolization, Principles and indications. 放射栓塞,原理和适应症。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-03-30 DOI: 10.1055/a-1759-4238
H. Ahmadzadehfar, H. Ilhan, M. Lam, M. Sraieb, L. Stegger
Radioembolization is the selective application of radionuclide-loaded microspheres into liver arteries for the therapy of liver tumours and metastases. In this review, we focused on therapy planning and dosimetry, as well as the main indications of 90Y-glass and resin microspheres and 166Ho-microspheres.
放射性栓塞是选择性应用放射性核素微球进入肝动脉治疗肝脏肿瘤和转移。本文综述了90y -玻璃和树脂微球和166ho -微球的治疗方案、剂量学以及主要适应症。
{"title":"Radioembolization, Principles and indications.","authors":"H. Ahmadzadehfar, H. Ilhan, M. Lam, M. Sraieb, L. Stegger","doi":"10.1055/a-1759-4238","DOIUrl":"https://doi.org/10.1055/a-1759-4238","url":null,"abstract":"Radioembolization is the selective application of radionuclide-loaded microspheres into liver arteries for the therapy of liver tumours and metastases. In this review, we focused on therapy planning and dosimetry, as well as the main indications of 90Y-glass and resin microspheres and 166Ho-microspheres.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"23 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88380494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine. 分化型甲状腺癌的个体化治疗:手术结合放射性碘成像和治疗的价值——来自外科和核医学的德国立场文件。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-03-17 DOI: 10.1055/a-1783-8154
M. Schmidt, P. Bartenstein, J. Bucerius, M. Dietlein, A. Drzezga, K. Herrmann, C. Lapa, K. Lorenz, T. Musholt, J. Nagarajah, C. Reiners, C. Sahlmann, M. Kreissl
A consensus statement about indications for post-surgical radioiodine therapy (RIT) in differentiated thyroid cancer patients (DTC) was recently published by the European Thyroid Association (ETA) 1. This publication discusses indications for RIT on the basis of an individual risk assessment. Many of the conclusions of this consensus statement are well founded and accepted across the disciplines involved. However, especially from the perspective of nuclear medicine, as the discipline responsible for indicating and executing RIT, some of the recommendations may require further clarification with regard to their compatibility with established best practice and national standards of care. Assessment of the indications for RIT is strongly dependent on the weighing up of benefits and risks. On the basis of longstanding clinical experience in nuclear medicine, RIT represents a highly specific precision medicine procedure of proven efficacy with a favorable side-effect profile. This distinguishes RIT significantly from other adjuvant oncological therapies and has resulted in the establishment of this procedure as a usually well-tolerated, standard safety measure. With regard to its favorable risk/benefit ratio, this procedure should not be unnecessarily restricted, in the interest of offering reassurance to the patients. Both patients' interests and regional/national differences need to be taken into account. We would therefore like to comment on the recent consensus from the perspective of authors and to provide recommendations based on the respective published data.
最近,欧洲甲状腺协会(ETA)发表了一份关于分化型甲状腺癌(DTC)术后放射性碘治疗(RIT)适应症的共识声明1。本出版物在个人风险评估的基础上讨论了RIT的适应症。这一共识声明的许多结论都是有充分根据的,并被所涉及的学科所接受。然而,特别是从核医学的角度来看,作为负责指示和执行RIT的学科,一些建议可能需要进一步澄清,以确定它们是否符合既定的最佳做法和国家护理标准。RIT适应症的评估在很大程度上取决于对益处和风险的权衡。根据核医学的长期临床经验,RIT代表了一种高度特异性的精确医学程序,已被证明有效且副作用良好。这将RIT与其他辅助肿瘤治疗明显区分开来,并导致RIT作为一种通常耐受良好的标准安全措施的建立。考虑到其有利的风险/收益比,为了给患者提供保证,不应不必要地限制该程序。患者的利益和地区/国家的差异都需要考虑。因此,我们想从作者的角度对最近的共识进行评论,并根据各自发表的数据提出建议。
{"title":"Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy - A German position paper from Surgery and Nuclear Medicine.","authors":"M. Schmidt, P. Bartenstein, J. Bucerius, M. Dietlein, A. Drzezga, K. Herrmann, C. Lapa, K. Lorenz, T. Musholt, J. Nagarajah, C. Reiners, C. Sahlmann, M. Kreissl","doi":"10.1055/a-1783-8154","DOIUrl":"https://doi.org/10.1055/a-1783-8154","url":null,"abstract":"A consensus statement about indications for post-surgical radioiodine therapy (RIT) in differentiated thyroid cancer patients (DTC) was recently published by the European Thyroid Association (ETA) 1. This publication discusses indications for RIT on the basis of an individual risk assessment. Many of the conclusions of this consensus statement are well founded and accepted across the disciplines involved. However, especially from the perspective of nuclear medicine, as the discipline responsible for indicating and executing RIT, some of the recommendations may require further clarification with regard to their compatibility with established best practice and national standards of care. Assessment of the indications for RIT is strongly dependent on the weighing up of benefits and risks. On the basis of longstanding clinical experience in nuclear medicine, RIT represents a highly specific precision medicine procedure of proven efficacy with a favorable side-effect profile. This distinguishes RIT significantly from other adjuvant oncological therapies and has resulted in the establishment of this procedure as a usually well-tolerated, standard safety measure. With regard to its favorable risk/benefit ratio, this procedure should not be unnecessarily restricted, in the interest of offering reassurance to the patients. Both patients' interests and regional/national differences need to be taken into account. We would therefore like to comment on the recent consensus from the perspective of authors and to provide recommendations based on the respective published data.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"27 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79248613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma. HRPT2突变患者的18F胆碱PET/CT:检测甲状旁腺癌复发和合并乳腺癌。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-02-01 Epub Date: 2021-11-29 DOI: 10.1055/a-1670-9315
Konrad Christof Radzikowski, Gundula Rendl, Mohsen Beheshti, Christian Pirich
{"title":"18F Choline PET/CT in a patient with HRPT2 mutation: Detecting parathyroid carcinoma recurrence and concomitant breast carcinoma.","authors":"Konrad Christof Radzikowski,&nbsp;Gundula Rendl,&nbsp;Mohsen Beheshti,&nbsp;Christian Pirich","doi":"10.1055/a-1670-9315","DOIUrl":"https://doi.org/10.1055/a-1670-9315","url":null,"abstract":"","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"62-64"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
[The Baker's cyst - a blunt sword of Damokles in radiosynoviorthesis (RSO)?] 贝克囊肿-放射滑膜术(RSO)中的一把钝剑?]
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-02-01 Epub Date: 2021-10-29 DOI: 10.1055/a-1650-9513
Willm Uwe Kampen, Lutz S Freudenberg, Manfred Fischer, Rigobert Klett

The existence of a popliteal Baker's cyst was regarded as a contraindication for radiosynoviorthesis of the knee joint since decades. A so-called "ventile mechanism" was discussed leading to a significant concentration of the intraarticularly applied, high energy beta emitting radiopharmaceutical yttrium-90-colloid in the cyst. This cyst arises from a bursa beneath the tendon of the medial head of the gastrocnemius muscle, normally communicating with the knee joint space. Since the cyst wall is much thinner than the knee joint capsule, a radiogenic rupture of the cyst was feared, leading to severe radiogenic necroses of the surrounding soft tissue. Due to this potential hazard, knee joint ultrasound is mandatory prior to radiosynoviorthesis to check for any popliteal cysts. New studies however decline the risk of a radiogenic cyst rupture after an appropriately performed radiosynoviorthesis of the knee joint.In case of a preexistent cyst rupture, the risk of a radiogenic tissue damage remains an issue and magnetic resonance imaging (MRI) is the method of choice to exclude this potential hazard. However, MRI sometimes leads to equivocal results. Scintigraphy of the knee joint after intraarticular application of Tc-99m-nanocolloid offers the possibility to check for the integrity of the Baker's cyst in these patients to be sure that radiosynoviorthesis will not lead to a relevant extraarticular leakage with soft tissue necroses. This study describes the procedure of intracavitary distribution scintigraphy by means of representative case reports.

腘窝贝克囊肿的存在被认为是几十年来放射性膝关节滑膜成形术的禁忌症。讨论了所谓的“通气机制”,导致囊肿内关节内应用的高能放射药物钇-90胶体的显著浓度。该囊肿起源于腓肠肌内侧头肌腱下方的囊,通常与膝关节间隙相通。由于囊肿壁比膝关节囊薄得多,因此担心囊肿会发生放射性破裂,导致周围软组织严重的放射性坏死。由于这种潜在的危险,在放射滑膜成形术之前,膝关节超声检查是否有腘窝囊肿是必须的。然而,新的研究表明,适当进行膝关节放射滑膜切开术后,放射源性囊肿破裂的风险降低。在先前存在的囊肿破裂的情况下,放射性组织损伤的风险仍然是一个问题,磁共振成像(MRI)是排除这种潜在危险的选择方法。然而,MRI有时会导致模棱两可的结果。在关节内应用tc -99m纳米胶体后,膝关节的闪烁成像为检查这些患者的贝克囊肿的完整性提供了可能性,以确保放射滑膜成形术不会导致相关的关节外渗漏和软组织坏死。本研究通过代表性病例报告,描述了腔内分布显像的程序。
{"title":"[The Baker's cyst - a blunt sword of Damokles in radiosynoviorthesis (RSO)?]","authors":"Willm Uwe Kampen,&nbsp;Lutz S Freudenberg,&nbsp;Manfred Fischer,&nbsp;Rigobert Klett","doi":"10.1055/a-1650-9513","DOIUrl":"https://doi.org/10.1055/a-1650-9513","url":null,"abstract":"<p><p>The existence of a popliteal Baker's cyst was regarded as a contraindication for radiosynoviorthesis of the knee joint since decades. A so-called \"ventile mechanism\" was discussed leading to a significant concentration of the intraarticularly applied, high energy beta emitting radiopharmaceutical yttrium-90-colloid in the cyst. This cyst arises from a bursa beneath the tendon of the medial head of the gastrocnemius muscle, normally communicating with the knee joint space. Since the cyst wall is much thinner than the knee joint capsule, a radiogenic rupture of the cyst was feared, leading to severe radiogenic necroses of the surrounding soft tissue. Due to this potential hazard, knee joint ultrasound is mandatory prior to radiosynoviorthesis to check for any popliteal cysts. New studies however decline the risk of a radiogenic cyst rupture after an appropriately performed radiosynoviorthesis of the knee joint.In case of a preexistent cyst rupture, the risk of a radiogenic tissue damage remains an issue and magnetic resonance imaging (MRI) is the method of choice to exclude this potential hazard. However, MRI sometimes leads to equivocal results. Scintigraphy of the knee joint after intraarticular application of Tc-99m-nanocolloid offers the possibility to check for the integrity of the Baker's cyst in these patients to be sure that radiosynoviorthesis will not lead to a relevant extraarticular leakage with soft tissue necroses. This study describes the procedure of intracavitary distribution scintigraphy by means of representative case reports.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"42-48"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39678365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. 转移性前列腺癌的Lu-177-PSMA-617放射配体治疗后的治疗结果和影响总生存的因素
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-02-01 Epub Date: 2021-12-16 DOI: 10.1055/a-1670-9500
Charlotte A Schneider, Philipp Täger, Jochen Hammes, Thomas Fischer, Alexander Drzezga, David Pfister, Axel Heidenreich, Matthias Schmidt

Objective: To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Patients and methods: Between November 2014 and December 2018, a total of 56 consecutive patients (median age 69.5 years; range 55-84 years) with mCRPC were included in this retrospective analysis. Patients received between 1 and 4 therapy cycles with a mean activity of 6.8 GBq per cycle. Biochemical response was evaluated using Prostate Cancer Working Group Criteria 3 (PCWG 3). Survival was assessed using Kaplan-Meier estimates and Cox proportional hazards regression analysis. This retrospective study was approved by the local ethics committee.

Results: A total of 139 treatment cycles with Lu-177-PSMA-617 were performed. A decline of 50% or more of prostate-specific antigen (PSA) level occurred in 54% and a PSA decline of any amount in 65% of patients. The estimated median overall survival (OS) was 16 months, in the chemotherapy subgroup 14 months. A longer OS was associated with a PSA-decline ≥50%, more than 2 cycles of therapy, cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l]. These identified predictors remained significant on uni- and multivariate Cox regression analysis. Moreover, 40% of the patients who were non-responders after the first therapy cycle turned into responders after the second one.

Conclusion: PSA-decline ≥50%, a cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l] were identified as key predictors of prolonged OS in patients with mCRPC. In contrast rapid clinical deterioration mostly due to skeletal carcinomatosis resulted in early treatment failure.

目的:探讨Lu-177-PSMA-617放射治疗转移性去势抵抗性前列腺癌(mCRPC)的临床疗效。患者和方法:2014年11月至2018年12月,共连续56例患者(中位年龄69.5岁;年龄55-84岁)的mCRPC患者纳入回顾性分析。患者接受1 - 4个治疗周期,每个周期的平均活度为6.8 GBq。使用前列腺癌工作组标准3 (PCWG 3)评估生化反应。使用Kaplan-Meier估计和Cox比例风险回归分析评估生存率。本回顾性研究得到了当地伦理委员会的批准。结果:Lu-177-PSMA-617共进行了139个治疗周期。54%的患者前列腺特异性抗原(PSA)水平下降50%或以上,65%的患者PSA有一定程度的下降。估计中位总生存期(OS)为16个月,化疗亚组为14个月。较长的生存期与psa下降≥50%、超过2个治疗周期、累积活性>15 GBq和初始碱性磷酸酶≤220 [U/l]相关。这些确定的预测因子在单因素和多因素Cox回归分析中仍然显著。此外,在第一个治疗周期后无反应的患者中有40%在第二个治疗周期后转为反应。结论:psa下降≥50%,累积活性>15 GBq,初始碱性磷酸酶≤220 [U/l]是mCRPC患者延长OS的关键预测因素。相反,由于骨癌的快速临床恶化导致早期治疗失败。
{"title":"Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer.","authors":"Charlotte A Schneider,&nbsp;Philipp Täger,&nbsp;Jochen Hammes,&nbsp;Thomas Fischer,&nbsp;Alexander Drzezga,&nbsp;David Pfister,&nbsp;Axel Heidenreich,&nbsp;Matthias Schmidt","doi":"10.1055/a-1670-9500","DOIUrl":"https://doi.org/10.1055/a-1670-9500","url":null,"abstract":"<p><strong>Objective: </strong>To examine the clinical benefit of Lu-177-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Patients and methods: </strong>Between November 2014 and December 2018, a total of 56 consecutive patients (median age 69.5 years; range 55-84 years) with mCRPC were included in this retrospective analysis. Patients received between 1 and 4 therapy cycles with a mean activity of 6.8 GBq per cycle. Biochemical response was evaluated using Prostate Cancer Working Group Criteria 3 (PCWG 3). Survival was assessed using Kaplan-Meier estimates and Cox proportional hazards regression analysis. This retrospective study was approved by the local ethics committee.</p><p><strong>Results: </strong>A total of 139 treatment cycles with Lu-177-PSMA-617 were performed. A decline of 50% or more of prostate-specific antigen (PSA) level occurred in 54% and a PSA decline of any amount in 65% of patients. The estimated median overall survival (OS) was 16 months, in the chemotherapy subgroup 14 months. A longer OS was associated with a PSA-decline ≥50%, more than 2 cycles of therapy, cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l]. These identified predictors remained significant on uni- and multivariate Cox regression analysis. Moreover, 40% of the patients who were non-responders after the first therapy cycle turned into responders after the second one.</p><p><strong>Conclusion: </strong>PSA-decline ≥50%, a cumulative activity >15 GBq and an initial alkaline phosphatase ≤ 220 [U/l] were identified as key predictors of prolonged OS in patients with mCRPC. In contrast rapid clinical deterioration mostly due to skeletal carcinomatosis resulted in early treatment failure.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"25-32"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39846664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
[Treatment Planning and Dose Verification for Combined Internal and External Radiotherapy (CIERT)]. [内外联合放疗(CIERT)的治疗计划和剂量验证]。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-02-01 Epub Date: 2021-11-29 DOI: 10.1055/a-1650-9428
Robert Freudenberg, Holger Hartmann, Michael Andreeff, Liane Oehme, Thomas Leichtner, Alexander Fischer, Timo Paulus, Mechthild Krause, Jörg Kotzerke

Aim: The combined internal and external radiotherapy (CIERT) take advantage of the benefits from radionuclide therapy and external beam irradiation. These include steep dose gradients and a low toxicity to normal tissue due to the use of unsealed radioisotopes as well as homogeneous dose distribution within the tumor due to external beam irradiation. For a combined irradiation planning, an infrastructure has to be developed that takes into account the dose contributions from both modalities. A physical verification of the absorbed dose distribution should follow by measurements using OSL detectors.

Method: Internal irradiation was performed using Re-188 in a cylindrical phantom with three inserts. SPECT images were acquired to calculate the internal dose using the software STRATOS. The dose distribution was exported as DICOM-RT data and imported in the software Pinnacle. Based on the internal dose distribution the external irradiation using 6 MV photons was planned. The dose contributions of both modalities separately as well as for combined irradiation was measured using OSL detectors made out of Beryllium oxide.

Results: The planed doses of combined irradiation (1 Gy, 2 Gy, 4 Gy) could be verified within the uncertainty of the detectors. The mean energy response to Re-188 was (88.6 ± 2.4) % with respect to the calibration with 200 kV X-ray irradiation. The energy response to 6 MV photons was (146.0 ± 4.9) %.

Conclusion: A workflow for the treatment planning of combined internal and external radiotherapy has been developed and tested. Measurements verified the calculated doses. Therefore, the physical and technical basis for the dosimetry of combined irradiation were worked out.

目的:内外联合放疗(CIERT)综合了放射性核素治疗和外照射的优点。这包括陡峭的剂量梯度和由于使用非密封放射性同位素对正常组织的低毒性,以及由于外部束照射在肿瘤内的均匀剂量分布。对于联合辐照规划,必须发展一种基础设施,考虑到两种方式的剂量贡献。在对吸收剂量分布进行物理验证之后,应使用OSL探测器进行测量。方法:采用Re-188对带3个植入物的圆柱形假体进行内照射。利用STRATOS软件获取SPECT图像计算内剂量。剂量分布导出为DICOM-RT数据,并在Pinnacle软件中导入。根据内部剂量分布,计划了6 MV光子的外照射。用氧化铍制成的OSL探测器分别测量了两种方式以及联合照射的剂量贡献。结果:计划辐照剂量(1 Gy、2 Gy、4 Gy)可在探测器的不确定度范围内进行验证。相对于200 kV x射线辐照校准,Re-188的平均能量响应为(88.6±2.4)%。对6 MV光子的能量响应为(146.0±4.9)%。结论:建立并测试了一套内外联合放疗的治疗计划工作流程。测量结果证实了所计算的剂量。从而为联合辐照的剂量学研究奠定了物理和技术基础。
{"title":"[Treatment Planning and Dose Verification for Combined Internal and External Radiotherapy (CIERT)].","authors":"Robert Freudenberg,&nbsp;Holger Hartmann,&nbsp;Michael Andreeff,&nbsp;Liane Oehme,&nbsp;Thomas Leichtner,&nbsp;Alexander Fischer,&nbsp;Timo Paulus,&nbsp;Mechthild Krause,&nbsp;Jörg Kotzerke","doi":"10.1055/a-1650-9428","DOIUrl":"https://doi.org/10.1055/a-1650-9428","url":null,"abstract":"<p><strong>Aim: </strong>The combined internal and external radiotherapy (CIERT) take advantage of the benefits from radionuclide therapy and external beam irradiation. These include steep dose gradients and a low toxicity to normal tissue due to the use of unsealed radioisotopes as well as homogeneous dose distribution within the tumor due to external beam irradiation. For a combined irradiation planning, an infrastructure has to be developed that takes into account the dose contributions from both modalities. A physical verification of the absorbed dose distribution should follow by measurements using OSL detectors.</p><p><strong>Method: </strong>Internal irradiation was performed using Re-188 in a cylindrical phantom with three inserts. SPECT images were acquired to calculate the internal dose using the software STRATOS. The dose distribution was exported as DICOM-RT data and imported in the software Pinnacle. Based on the internal dose distribution the external irradiation using 6 MV photons was planned. The dose contributions of both modalities separately as well as for combined irradiation was measured using OSL detectors made out of Beryllium oxide.</p><p><strong>Results: </strong>The planed doses of combined irradiation (1 Gy, 2 Gy, 4 Gy) could be verified within the uncertainty of the detectors. The mean energy response to Re-188 was (88.6 ± 2.4) % with respect to the calibration with 200 kV X-ray irradiation. The energy response to 6 MV photons was (146.0 ± 4.9) %.</p><p><strong>Conclusion: </strong>A workflow for the treatment planning of combined internal and external radiotherapy has been developed and tested. Measurements verified the calculated doses. Therefore, the physical and technical basis for the dosimetry of combined irradiation were worked out.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"49-57"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39943984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Diagnostic Value of Bone SPECT/CT Using 99mTc-Methylene Diphosphonate in Patients with Unspecified Chest Wall Pain. 99mtc -二膦酸亚甲基骨SPECT/CT对不明胸壁痛的诊断价值。
IF 1.5 4区 医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2022-02-01 Epub Date: 2021-11-12 DOI: 10.1055/a-1549-5910
Soo Bin Park, Chae Hong Lim, Won Ho Chang, Jung Hwa Hwang, Ji Young Lee, Young Hwan Kim, Jung Mi Park

Purpose: We investigated the diagnostic performance of single photon emission computed tomography (SPECT)/computed tomography (CT) as a combination of functional and anatomic imaging, in patients with unspecified chest wall pain.

Methods: Fifty-two patients with unspecified chest wall pain and no history of recent major traumatic events or cardiac disease were included. The number and location of radioactive chest wall lesions were evaluated on both planar images and SPECT/CT. The clinical diagnosis was made based on all of the clinical and imaging data and follow-up information.

Results: Chest wall diseases were diagnosed in 42 patients (80.8 %). SPECT/CT showed abnormal findings in 35 (67.3 %) patients with positive predictive value (PPV) of 97.1 %. SPECT/CT revealed 56 % more lesions than planar bone scan (P = 0.002) and most of the abnormal radioactive lesions (94.6 %) showed combined morphological changes on the matched CT component. When comparing between age subgroups (< 60 y vs. ≥ 60 y), the prevalence of chest wall disease and diagnosis rate of fracture was significantly higher in the older age group. On SPECT/CT, the older age group showed higher frequency of having abnormal finding (95.8 % vs. 42.9 %, P < 0.001) and significantly more lesions were detected (a total of 189 vs. 32, P = 0.003).

Conclusion: SPECT/CT showed good diagnostic performance and proved to have higher sensitivity, detecting 56 % more lesions than planar bone scan. A negative result could be helpful for excluding pathologic chest wall disease. SPECT/CT might be recommended for integration in to the diagnostic workup in patients with unspecified chest wall pain, especially in patients ≥ 60 y of age, considering the high disease prevalence and the high frequency of positive results.

目的:研究单光子发射计算机断层扫描(SPECT)/计算机断层扫描(CT)作为功能和解剖成像的结合对不明原因胸壁疼痛患者的诊断价值。方法:纳入52例胸壁疼痛不明,近期无重大创伤事件或心脏疾病史的患者。在平面图像和SPECT/CT上评估胸壁放射性病变的数量和位置。临床诊断是基于所有的临床和影像学资料和随访信息。结果:胸壁病变42例(80.8%)。SPECT/CT异常35例(67.3%),阳性预测值(PPV)为97.1%。SPECT/CT显示病变比平面骨扫描多56% (P = 0.002),大多数异常放射性病变(94.6%)在匹配的CT分量上表现为复合形态改变。在年龄亚组间比较(< 60岁vs≥60岁),老年组胸壁疾病患病率和骨折诊断率明显高于老年组。在SPECT/CT上,老年组异常发现的频率更高(95.8%比42.9%,P < 0.001),检出的病变明显更多(189比32,P = 0.003)。结论:SPECT/CT具有较好的诊断性能和较高的灵敏度,病灶检出率比平面骨扫描高56%。阴性结果有助于排除病理性胸壁疾病。考虑到该病的高患病率和阳性结果的高频率,可能建议将SPECT/CT纳入未明确胸壁疼痛患者的诊断工作中,特别是年龄≥60岁的患者。
{"title":"Diagnostic Value of Bone SPECT/CT Using 99mTc-Methylene Diphosphonate in Patients with Unspecified Chest Wall Pain.","authors":"Soo Bin Park,&nbsp;Chae Hong Lim,&nbsp;Won Ho Chang,&nbsp;Jung Hwa Hwang,&nbsp;Ji Young Lee,&nbsp;Young Hwan Kim,&nbsp;Jung Mi Park","doi":"10.1055/a-1549-5910","DOIUrl":"https://doi.org/10.1055/a-1549-5910","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the diagnostic performance of single photon emission computed tomography (SPECT)/computed tomography (CT) as a combination of functional and anatomic imaging, in patients with unspecified chest wall pain.</p><p><strong>Methods: </strong>Fifty-two patients with unspecified chest wall pain and no history of recent major traumatic events or cardiac disease were included. The number and location of radioactive chest wall lesions were evaluated on both planar images and SPECT/CT. The clinical diagnosis was made based on all of the clinical and imaging data and follow-up information.</p><p><strong>Results: </strong>Chest wall diseases were diagnosed in 42 patients (80.8 %). SPECT/CT showed abnormal findings in 35 (67.3 %) patients with positive predictive value (PPV) of 97.1 %. SPECT/CT revealed 56 % more lesions than planar bone scan (<i>P</i> = 0.002) and most of the abnormal radioactive lesions (94.6 %) showed combined morphological changes on the matched CT component. When comparing between age subgroups (< 60 y vs. ≥ 60 y), the prevalence of chest wall disease and diagnosis rate of fracture was significantly higher in the older age group. On SPECT/CT, the older age group showed higher frequency of having abnormal finding (95.8 % vs. 42.9 %, <i>P</i> < 0.001) and significantly more lesions were detected (a total of 189 vs. 32, <i>P</i> = 0.003).</p><p><strong>Conclusion: </strong>SPECT/CT showed good diagnostic performance and proved to have higher sensitivity, detecting 56 % more lesions than planar bone scan. A negative result could be helpful for excluding pathologic chest wall disease. SPECT/CT might be recommended for integration in to the diagnostic workup in patients with unspecified chest wall pain, especially in patients ≥ 60 y of age, considering the high disease prevalence and the high frequency of positive results.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 1","pages":"16-24"},"PeriodicalIF":1.5,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39616020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nuklearmedizin-nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1